Earnings results for Repligen (NASDAQ:RGEN)
Repligen Corporation is expected* to report earnings on 05/04/2021 before market open. The report will be for the fiscal Quarter ending Mar 2021. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.43. The reported EPS for the same quarter last year was $0.32.
Repligen last posted its earnings results on February 23rd, 2021. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.21. The company earned $108.65 million during the quarter, compared to analyst estimates of $93.89 million. Repligen has generated $1.07 earnings per share over the last year and currently has a price-to-earnings ratio of 258.2. Repligen has confirmed that its next quarterly earnings report will be published on Tuesday, May 4th, 2021. Repligen will be holding an earnings conference call on Tuesday, May 4th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Repligen (NASDAQ:RGEN)
5 Wall Street analysts have issued ratings and price targets for Repligen in the last 12 months. Their average twelve-month price target is $219.00, predicting that the stock has a possible upside of 3.44%. The high price target for RGEN is $251.00 and the low price target for RGEN is $150.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Repligen has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $219.00, Repligen has a forecasted upside of 3.4% from its current price of $211.71. Repligen has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: Repligen (NASDAQ:RGEN)
Repligen does not currently pay a dividend. Repligen does not have a long track record of dividend growth.
Insiders buying/selling: Repligen (NASDAQ:RGEN)
In the past three months, Repligen insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,056,388.00 in company stock. Only 1.70% of the stock of Repligen is held by insiders. 84.33% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Repligen (NASDAQ:RGEN
Earnings for Repligen are expected to grow by 15.28% in the coming year, from $1.44 to $1.66 per share. The P/E ratio of Repligen is 258.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.00. The P/E ratio of Repligen is 258.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 44.52. Repligen has a PEG Ratio of 4.18. PEG Ratios above 1 indicate that a company could be overvalued. Repligen has a P/B Ratio of 10.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here